Research
Molecular
AM833 is a novel nonselective agonist of calcitonin family receptors that has demonstrated efficacy for the treatment of obesity in phase 2 clinical trials.
AM833 may be a promising treatment option for obesity management.
StrongSupportsmedium confidence
AM833 is a novel nonselective agonist of calcitonin family receptors that has demonstrated efficacy for the treatment of obesity in phase 2 clinical trials.
Why this rating
The claim is based on phase 2 clinical trials.
Source
AM833 Is a Novel Agonist of Calcitonin Family G Protein–Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists
Madeleine M. Fletcher et al. · Journal of Pharmacology and Experimental Therapeutics · 2021
otherCited 65×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →